EGFR and lung carcinoma: The therapeutic methods targeting mutation-induced EGFR activation have exhibited great success in clinics for lung cancer patients harboring EGFR mutations, therefore, raising the opportunities to guide the targeted therapies for NSCLC patients who have the EGFR mutations.